Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
Launched by XUANWU HOSPITAL, BEIJING ยท
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special type of brain stimulation called transcranial ultrasound stimulation (TUS) can help improve thinking and memory problems often called "brain fog" in people who have had COVID-19. Brain fog is a common symptom of long COVID, where people experience difficulty concentrating, remembering things, or processing information. The researchers want to find out if targeting a specific part of the brain with this ultrasound treatment can reduce these symptoms and improve cognitive function.
Anyone aged between 18 and 74 years old who is experiencing ongoing brain fog after COVID-19 may be eligible to join the study. Participants will first complete some tests to measure how severe their brain fog is and perform tasks that assess their thinking skills while their brain activity is recorded. Some will receive the actual ultrasound treatment, while others will get a placebo (a sham treatment) to compare results. The treatment session is brief, lasting about 60 seconds, and participants will have brain scans before and after to see if there are changes. This study is currently recruiting volunteers and could offer new hope for those struggling with long-term cognitive effects after COVID-19.
Gender
ALL
Eligibility criteria
About Xuanwu Hospital, Beijing
Xuanwu Hospital, located in Beijing, is a leading clinical research institution renowned for its commitment to advancing medical knowledge and improving patient care. Affiliated with Capital Medical University, the hospital specializes in neurology and rehabilitation, providing a robust framework for innovative clinical trials. With a multidisciplinary team of experienced researchers and healthcare professionals, Xuanwu Hospital focuses on conducting high-quality, ethically sound studies that aim to explore new treatment modalities and enhance therapeutic outcomes. Through its dedication to research excellence and patient-centered approaches, Xuanwu Hospital plays a pivotal role in the advancement of healthcare solutions both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yi Tang, MD., PhD
Principal Investigator
Xuanwu Hospital, Beijing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported